Back to News
Market Impact: 0.2
Canaccord Genuity Initiates Coverage of Tonix Pharmaceuticals Holding with Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Canaccord Genuity initiated coverage of Tonix Pharmaceuticals with a Buy recommendation on October 26, 2026. The stock's last reported close was $5.17 on October 23; the article excerpt provides no subsequent price reaction or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
TNXP0.45
More News
- Why is PagSeguro Digital stock plummeting 30% today?
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Carnage beneath the record high: How to find cheap stocks without the traps
- Buy Tesla ahead of potential SpaceX merger, says Barclays
- As AI becomes more fractured, one names stands out: AMD
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock